Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Pandoraon Apr 24, 2022 3:44pm
139 Views
Post# 34627520

RE:RE:RE:RE:BTD timeline...

RE:RE:RE:RE:BTD timeline...Sorry Eoganacht but I still get confused over quotes regarding numbers of patients. I never know if we are talking only about "optimized" treatment patients of Phase 2 or "all" patients and if the Phase 1b patients are ever included as part of "all" or not.

Your quote:

"The 25th patient received the 90 day assessment in December 2021. So before the end of 2022 Theralase will be able to submit 360 day data on the first 25 patients to the FDA."

Your reference here to the '25th patient' and to 'the first 25 patients' -- does that, or does that not, include the 12 patients that did not receive the correct dosages i.e. 'non-optimized' at the start of phase 2?

Below is your post from April 18 referring to 23 patients and the 82% CR:(again I am not sure which 23 patients are addressed here -- maybe it's just me, but I feel others may not be completely sure either) Are they Patients #1 - 23 in Study II or are they Patients #13 - 36 in Study II or a mix? I believe the "total" number that had been referenced was 38 but I believe that total number included Patients #5 & 6 from Study 1b:

One more look at the new 90 day optimized data

I changed the percentages to patient counts for the recent 90 day numbers for the:

23 patients enrolled and treated in Study II who received an optimized primary study treatment

CR
= 12
PR = 4
Pending = 3
NR = 4
Potential CR = 82%

In the last newsletter there were 18 post-Aug 20 2020 optimized patients

CR
= 8
PR = 2
Pending = 7
NR = 1
Potential CR = 94.4%

In the period between the two news releases 7 patients reached 90 days and 5 more patients were treated for a total of 12 patients. Of these 12 patients there were:

CR = 4
PR = 2
Pending = 3
NR = 3
Potential CR = 75%

Out of these 12 patients 3 patients (25%) were NR. The results of just these 3 patients accounts for the drop in 90 day potential CR. We will probably never know what happened with these 3 probably very sick and elderly patients but given where we are in the trial it will likely have little overall effect. If you flip a coin 12 times you won't likely get 6 heads and 6 tails. You might get 4 tails and 8 heads. But if you fip a coin 100 times it will be much closer to 50% heads and 50% tails. If those 3 patients had been CR or PR we would have a 90 day potential CR of 96% and the sp would have reached new heights IMHO. But this isn't the first time Theralase's sp has taken an unexpected and unwarranted hit.
<< Previous
Bullboard Posts
Next >>